Stage IV uveal melanoma at initial presentation (group M)
| AJCC tumour category | Choroidal n=55 | Ciliary body n=11 | Iris n=3 | Total n=69 | ||
| T-category | T1a | No CBI/ESE | 4 (7%) | 0 (0%) | 0 (0%) | 4 (6%) |
| T1b | CBI only | 0 (0%) | 1 (9%) | 2 (67%) | 3 (4%) | |
| T1c | ESE only (≤5 mm) | 1 (2%) | 0 (0%) | 0 (0%) | 1 (1%) | |
| T1d | Both CBI and ESE (≤5 mm) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | |
| T2a | No CBI/ESE | 17 (31%) | 0 (0%) | 0 (0%) | 17 (26%) | |
| T2b | CBI only | 0 (0%) | 2 (18%) | 0 (0%) | 2 (3%) | |
| T2c | ESE only (≤5 mm) | 1 (2%) | 0 (0%) | 0 (0%) | 1 (1%) | |
| T2d | Both CBI and ESE (≤5 mm) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | |
| T3a | No CBI/ESE | 13 (27%) | 0 (0%) | 0 (0%) | 13 (19%) | |
| T3b | CBI only | 2 (4%) | 3 (27%) | 0 (0%) | 5 (7%) | |
| T3c | ESE only (≤5 mm) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | |
| T3d | Both CBI and ESE (≤5 mm) | 1 (2%) | 4 (36%) | 0 (0%) | 5 (7%) | |
| T4a | No CBI/ESE | 8 (14%) | 0 (0%) | 1 (33%) | 9 (13%) | |
| T4b | CBI only | 5 (9%) | 0 (0%) | 0 (0%) | 5 (7%) | |
| T4c | ESE only (≤5 mm) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | |
| T4d | Both CBI and ESE (≤5 mm) | 2 (4%) | 0 (0%) | 0 (0%) | 2 (3%) | |
| T4e | ESE (>5 mm) | 1 (2%) | 1 (9%) | 0 (0%) | 2 (3%) | |
| Metastasis sites | Regional lymph nodes (N1a) | 5 (9%) | 4 (36%) | 0 (0%) | 9 (13%) | |
| Liver | 38 (69%) | 9 (82%) | 3 (100%) | 50 (72%) | ||
| Lung | 3 (5%) | 0 (0%) | 0 (0%) | 3 (4%) | ||
| Bone | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | ||
| Brain | 0 (0%) | 0 (0%) | 0 (0%) | (0%) | ||
| Subcutaneous tissue | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | ||
| Other sites | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | ||
| Multiple sites | 14 (26%) | 2 (18%) | 0 (0%) | 16 (24%) | ||
AJCC, American Joint Committee on Cancer, 8th edition; CBI, ciliary body involvement; ESE, extrascleral extension.